TRAIL-R1 polymorphisms and cancer susceptibility: An evidence-based meta-analysis

European Journal of Cancer

Volumn 45, Issue 14, 2009, Pages 2598-2605

  Chen, Bo ^a   Liu, Shan ^a   Wang, Xue Li ^a   Xu, Wei ^a   Li, Yan ^a   Zhao, Wei Hong ^a   Wu, Jian Qing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cancer susceptibility; Meta analysis; Polymorphism; TRAIL R1

Indexed keywords

DEATH RECEPTOR 4;

ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; GENETIC HETEROGENEITY; GENETIC MODEL; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOTE; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; EVIDENCE-BASED MEDICINE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; POLYMORPHISM, GENETIC; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RISK;

EID: 69249116239     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.06.023     Document Type: Article

References (32)

1. Wiley S.R., Schooley K., Smolak P.J., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
2. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., and Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271 (1996) 12687-12690
3. Mongkolsapaya J., Grimes J.M., Chen N., et al. Structure of the TRAILDR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol 6 (1999) 1048-1053
4. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
5. Almasan A., and Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14 (2003) 337-348
6. Pan G., O'Rourke K., Chinnaiyan A.M., et al. The receptor for the cytotoxic ligand TRAIL. Science 276 (1997) 111-113
7. Hymowitz S.G., Christinger H.W., Fuh G., et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 4 (1999) 563-571
8. Fisher M.J., Virmani A.K., Wu L., et al. Nucleotide substitution in the ectodomain of TRAIL receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 7 (2001) 1688-1697
9. Seitz S., Wassmuth P., Fischer J., et al. Mutation analysis and mRNA expression of trail-receptors in human breast cancer. Int J Cancer 102 (2002) 117-128
10. Lee S.H., Shin M.S., Kim H.S., et al. Somatic mutations of TRAIL receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 20 (2001) 399-403
11. Hazra A., Chamberlain R.M., Grossman H.B., Zhu Y., Spitz M.R., and Wu X. Death receptor 4 and bladder cancer risk. Cancer Res 63 (2003) 1157-1159
12. Wolf S., Mertens D., Pscherer A., et al. Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int J Cancer 118 (2006) 1831-1835
13. Fernàndez V., Jares P., Beà S., et al. Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms. Haematologica 89 (2004) 1322-1331
14. Horak P., Pils D., Roessler M., et al. Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer. Gynecol Oncol 97 (2005) 514-518
15. Frank B., Shanmugam K.S., Beckmann L., et al. Death receptor 4 variants and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 15 (2006) 2002-2005
16. Kuraoka K., Matsumura S., Sanada Y., et al. A single nucleotide polymorphism in the extracellular domain of TRAIL receptor DR4 at nucleotide 626 in gastric cancer patients in Japan. Oncol Rep 14 (2005) 465-470
17. Lu G., Bing X., Qi S., and Chun L. Association of DR4 gene polymorphism in Chinese patients with gastroduodenal diseases. Med J Wuhan Univ 28 (2007) 93-95
18. Frank B., Hemminki K., Shanmugam K.S., et al. Association of death receptor 4 haplotype 626C-683C with an increased breast cancer risk. Carcinogenesis 26 (2005) 1975-1977
19. Martinez-Ferrandis J.I., Rodríguez-López R., Milne R.L., et al. Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women. Cancer Biomark 3 (2007) 89-93
20. Persson I. Estrogens in the causation of breast, endometrial and ovarian cancers-evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 74 (2000) 357-364
21. Mizoue T., Inoue M., Tanaka K., et al. Tobacco smoking and colorectal cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol 36 (2006) 25-39
22. Cohen S.M., Shirai T., and Steineck G. Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol 205 Suppl. (2000) 105-115
23. Tuyns A.J., Estève J., and Raymond L. Et al. Cancer of the larynx/hypopharynx, tobacco and alcohol: IARC international case-control study in Turin and Varese (Italy). Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France). Int J Cancer 41 (1988) 483-491
24. Cochran W.G. The combination of estimates from different experiments. Biometrics 10 (1954) 101-129
25. Mantel N., and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22 (1959) 719-748
26. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
27. Egger M., Davey Smith G., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
28. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
29. Evan G.I., and Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 411 (2001) 342-348
30. Bouralexis S., Findlay D.M., and Evdokiou A. Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis 10 (2005) 35-51
31. Koornstra J.J., Jalving M., Rijcken F.E., et al. Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction. Eur J Cancer 41 (2005) 1195-1202
32. Koornstra J.J., Kleibeuker J.H., van Geelen C.M., et al. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 200 (2003) 327-335